Serial FDG-PET to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)
- Resource Type
- Authors
- Julie Gralow; Erin K. Schubert; Lisa K. Dunnwald; David A. Mankoff; G. K. Ellis; Hannah M. Linden; Robert B. Livingston; S. Tam
- Source
- Journal of Clinical Oncology. 23:633-633
- Subject
- Cancer Research
medicine.medical_specialty
education.field_of_study
medicine.diagnostic_test
business.industry
Time to progression
Medical record
Population
Outcome measures
Standardized uptake value
medicine.disease
Metastatic breast cancer
Breast cancer
Oncology
Positron emission tomography
medicine
Radiology
business
Nuclear medicine
education
- Language
- ISSN
- 1527-7755
0732-183X
633 Background: The response of bone-dominant breast cancer to therapy is difficult to assess by conventional imaging approaches such as bone scan and MRI. Our preliminary studies have previously shown that quantitative serial [F-18]-2-fluoro-D-glucose positron emission tomography (FDG PET) correlates with therapeutic response of bone-dominant breast cancer, but the relationship to long-term outcome measures is unknown. The aim of this study is to evaluate the prognostic power of FDG PET imaging in bone-dominant breast cancer undergoing treatment. Methods: A retrospective analysis was performed on the medical records of 405 breast cancer patients who were previously referred for FDG PET between January 1999 and December 2003. From this population of patients, 29 patients were selected who demonstrated metastatic bone only +/- nodal breast cancer and were undergoing treatment with at least 2 serial PET scans which had clear uptake. The standard uptake value (SUV) changes for the most conspicuous bone lesio...